TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer

What is the purpose of this trial?

This study will examine the safety and effectiveness of oxaliplatin in combination with TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has progressed or recurred after FOLFOX chemotherapy.



Yale Cancer Center

Start Date: 08/19/2016

End Date: 07/31/2019

Last Updated: 02/22/2018

Study HIC#: 1605017852

Get Involved

For more information about this study, contact:
Kamil Sadowski
+1 203-785-6661
kamil.sadowski@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image